论文部分内容阅读
采用肝动脉灌注化疗(HAI)和栓塞(HAE)治疗肝癌,是国内外近年开展的一种新疗法,获得了良好的效果,显示出可喜的发展前途。我们为104例(234次)肝癌病人作了HAI+HAE治疗或HAI治疗。为了进一步提高本法疗效和减少并发症,就其栓塞适应证和有关技术问题作如下探讨:1 适应证和禁忌证 HAE除了具备HAI的条件外,还应注意如下几点:1.1 肝动静脉瘘 由于癌组织侵蚀与破坏和解剖等因素可产生动静脉瘘发生血流短路。随肿瘤生长部位不同,发生在肝动静脉大小分支的任何部位。
The use of hepatic arterial infusion chemotherapy (HAI) and embolization (HAE) for the treatment of liver cancer is a new therapy developed at home and abroad in recent years, and has achieved good results, showing promising development prospects. We treated HAI+HAE or HAI for 104 patients (234) liver cancer patients. In order to further improve the efficacy of this method and reduce complications, the following indications are made for indications of embolism and related technical problems: 1 In addition to the conditions for HAI, indications and contraindications for HAE should be noted as follows: 1.1 Liver arteriovenous fistula Due to factors such as erosion and destruction of cancerous tissue and anatomy, arteriovenous fistulas can produce blood flow short circuits. With the site of tumor growth, it occurs in any part of the hepatic artery and vein size branch.